Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-1β AcTakine
- Development stage
- Preclinical
- Lead developer
- Orionis Biosciences
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
IL-1β AcTakine is a research-stage biologic developed by Orionis Biosciences using its proprietary AcTakine ('Activity-on-Target cytokine') platform. It is a fusion protein consisting of a low-activity mutant form of interleukin-1β (IL-1β) linked to a cell type-specific single-domain antibody (sdAb) that targets CD8+ T cells. This design allows for the selective delivery of IL-1β signaling to antitumor CD8+ T cells while minimizing systemic toxicity and off-target effects typically associated with native IL-1β. In preclinical models of melanoma and lung carcinoma, IL-1β AcTakine has demonstrated the ability to drive T cell proliferation and effector functionality, showing significant synergy when combined with other immunotherapies like neovasculature-targeted TNF AcTakines.
- Other names
- IL-1β-based AcTakine
02
Targets
IL-1R (Interleukin-1 receptor type 1 (IL-1R1))CD8A (T-cell surface glycoprotein CD8 alpha chain)
Beyond the preview
Go deeper on IL-1β AcTakine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-1β AcTakine.